source
- Agios ends development of tebapivat in low-risk MDS following subpar resultsAgios Pharmaceuticals has said it will stop developing its rare blood disorder drug for certain patients with myelodysplastic syndromes (MDS) due to disappointing Phase 2b data. The biotech’s pyruv…Endpoints · 2mo ago↗ source
- #ASCO26: Bristol Myers details Phase 3 trial win for Pomalyst successorBristol Myers Squibb’s next-gen multiple myeloma drug cut the risk of disease progression or death for certain patients by 52% when added on top of a combination treatment regimen. The New Jersey p…Endpoints · 2mo ago↗ source
- David Chang to hand over the reins at Allogene; Ex-Esperion CEO gets started at PhlowLongtime Allogene CEO David Chang will be stepping down at the end of June. Chang has served as the company’s CEO for the past eight years and will be succeeded by ...